KYMR

Kymera Therapeutics, Inc.

31.78 USD
-0.04 (-0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kymera Therapeutics, Inc. stock is down -11.75% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.

  • HC Wainwright & Co.
    Mon Jun 17, 06:51
    buy
    confirm
  • HC Wainwright & Co.
    Mon Jun 3, 06:52
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 24, 07:02
    buy
    confirm